181 related articles for article (PubMed ID: 30327943)
1. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.
Langenhorst JB; Dorlo TPC; van Maarseveen EM; Nierkens S; Kuball J; Boelens JJ; van Kesteren C; Huitema ADR
Clin Pharmacokinet; 2019 May; 58(5):627-637. PubMed ID: 30327943
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.
Langenhorst JB; van Kesteren C; van Maarseveen EM; Dorlo TPC; Nierkens S; Lindemans CA; de Witte MA; van Rhenen A; Raijmakers R; Bierings M; Kuball J; Huitema ADR; Boelens JJ
Blood Adv; 2019 Jul; 3(14):2179-2187. PubMed ID: 31324638
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.
Ivaturi V; Dvorak CC; Chan D; Liu T; Cowan MJ; Wahlstrom J; Stricherz M; Jennissen C; Orchard PJ; Tolar J; Pai SY; Huang L; Aweeka F; Long-Boyle J
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1701-1713. PubMed ID: 28684371
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation.
Wang H; Jones AK; Dvorak CC; Huang L; Orchard P; Ivaturi V; Long-Boyle J
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1603-1610. PubMed ID: 31002993
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients.
Chung H; Hong KT; Lee JW; Rhee SJ; Kim S; Yoon SH; Yu KS; Kang HJ
Bone Marrow Transplant; 2019 Feb; 54(2):284-292. PubMed ID: 29915216
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.
Bartelink IH; van Reij EM; Gerhardt CE; van Maarseveen EM; de Wildt A; Versluys B; Lindemans CA; Bierings MB; Boelens JJ
Biol Blood Marrow Transplant; 2014 Mar; 20(3):345-53. PubMed ID: 24315842
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients.
Nijstad AL; Nierkens S; Lindemans CA; Boelens JJ; Bierings M; Versluys AB; van der Elst KCM; Huitema ADR
Br J Clin Pharmacol; 2021 Aug; 87(8):3218-3226. PubMed ID: 33444472
[TBL] [Abstract][Full Text] [Related]
8. Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.
Sanghavi K; Wiseman A; Kirstein MN; Cao Q; Brundage R; Jensen K; Rogosheske J; Kurtzweil A; Long-Boyle J; Wagner J; Warlick ED; Brunstein CG; Weisdorf DJ; Jacobson PA
Transl Res; 2016 Sep; 175():103-115.e4. PubMed ID: 27094990
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of non-fludarabine versus fludarabine-based stem cell transplantation without total body irradiation in Fanconi anemia patients.
Hamidieh AA; Alimoghaddam K; Jahani M; Mousavi SA; Iravani M; Bahar B; Jalili M; Jalali A; Behfar M; Ghavamzadeh A
Hematol Oncol Stem Cell Ther; 2011; 4(3):109-15. PubMed ID: 21982883
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine/Melphalan 100 mg/m
Park HS; Lee JH; Lee JH; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1116-1121. PubMed ID: 30508593
[TBL] [Abstract][Full Text] [Related]
11. Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.
McCune JS; Mager DE; Bemer MJ; Sandmaier BM; Storer BE; Heimfeld S
Cancer Chemother Pharmacol; 2015 Jul; 76(1):85-96. PubMed ID: 25983023
[TBL] [Abstract][Full Text] [Related]
12. Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation.
de Castro FA; Lanchote VL; Voltarelli JC; Colturato VA; Simões BP
J Clin Pharmacol; 2013 Nov; 53(11):1205-11. PubMed ID: 23955479
[TBL] [Abstract][Full Text] [Related]
13. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Russell JA; Tran HT; Quinlan D; Chaudhry A; Duggan P; Brown C; Stewart D; Ruether JD; Morris D; Glick S; Gyonyor E; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):468-76. PubMed ID: 12374451
[TBL] [Abstract][Full Text] [Related]
14. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
Bartelink IH; Boelens JJ; Bredius RG; Egberts AC; Wang C; Bierings MB; Shaw PJ; Nath CE; Hempel G; Zwaveling J; Danhof M; Knibbe CA
Clin Pharmacokinet; 2012 May; 51(5):331-45. PubMed ID: 22455797
[TBL] [Abstract][Full Text] [Related]
15. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
[TBL] [Abstract][Full Text] [Related]
16. Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.
Pasquini MC; Le-Rademacher J; Zhu X; Artz A; DiPersio J; Fernandez HF; Mineishi S; Kamishohara M; Mehta J; Nakamura Y; Ratanatharathorn V; Sobecks R; Burkart J; Bredeson C
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1424-1430. PubMed ID: 27154848
[TBL] [Abstract][Full Text] [Related]
17. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.
Perkins JB; Kim J; Anasetti C; Fernandez HF; Perez LE; Ayala E; Kharfan-Dabaja MA; Tomblyn MR; Sullivan DM; Pidala JA; Field TL
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1099-107. PubMed ID: 22198540
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes.
Perkins J; Field T; Kim J; Kharfan-Dabaja MA; Ayala E; Perez L; Fernandez H; Fancher K; Tate C; Shaw LM; Milone MC; Gardiner JA; Miller S; Anasetti C
Bone Marrow Transplant; 2011 Nov; 46(11):1418-25. PubMed ID: 21132026
[TBL] [Abstract][Full Text] [Related]
20. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
